Exciting advancements in gastric cancer prevention are on the horizon with the development of an oral vaccine that shows 70% efficacy against H. Pylori. This innovative approach not only targets the gastrointestinal bacteria directly but also simplifies administration, making it accessible without specialized medical personnel. As research continues to uncover the links between infectious diseases and cancer, the potential impact of this vaccine could be significant.
